Welcome to the LHON Knowledge Hub

Evidence-based information for LHON carriers and healthcare providers focused on maintaining vision health through proper management and avoidance of triggers.

Summary


Pathophysiology & Complex I


Complex I Function in Health vs. LHON

Healthy Complex I Function

In healthy mitochondria, Complex I operates as the largest and most complex enzyme of the electron transport chain. It catalyzes the transfer of electrons from NADH to ubiquinone (CoQ10) through a sophisticated mechanism involving multiple iron-sulfur clusters and flavin mononucleotide (FMN). The process follows the "quinol-triggered semi-automatic shotgun model" where electron transfer is coupled to proton pumping across the inner mitochondrial membrane.

The healthy Complex I structure contains 45 subunits, with 7 core subunits (ND1, ND2, ND3, ND4, ND4L, ND5, and ND6) encoded by mitochondrial DNA. These subunits form the proton-pumping machinery that creates the electrochemical gradient essential for ATP synthesis. The electron transfer occurs through a series of iron-sulfur clusters with minimal electron leakage and ROS production.

LHON Mutations and Complex I Dysfunction

LHON mutations primarily affect three critical subunits: ND1 (3460G>A), ND4 (11778G>A), and ND6 (14484T>C). These mutations disrupt the quinol-triggered mechanism in distinct ways:

  • ND4 mutations (11778G>A): Severely impair proton pumping by disrupting the coupling between electron transfer and proton translocation, reducing ATP synthesis by 60-80%
  • ND1 mutations (3460G>A): Block the quinone binding chamber, preventing proper electron transfer from the iron-sulfur clusters to ubiquinone
  • ND6 mutations (14484T>C): Disrupt Complex I assembly and stability, leading to reduced overall enzyme function

The disrupted electron transport leads to electron leakage at the flavin site, generating excessive superoxide radicals. This ROS production overwhelms cellular antioxidant defenses, causing lipid peroxidation, mitochondrial DNA damage, and ultimately retinal ganglion cell apoptosis through the intrinsic apoptotic pathway.

Supplements & Therapeutic Strategies


Primary Evidence-Based Treatments

Therapeutic options with strongest evidence for LHON carriers:

Emerging / Limited-Evidence Options

Supplements with preliminary evidence or theoretical benefit - discuss with your healthcare provider:

Testosterone & Males


⚠️ Critical Warning for Male LHON Carriers

Supraphysiological testosterone levels may cause worsening of symptoms or trigger disease onset in LHON carriers. Male carriers considering testosterone therapy should be aware of the significant risks based on scientific evidence.

What LHON Carriers Should Avoid


LHON carriers should avoid the following substances and behaviors that may increase disease penetrance or worsen symptoms:

Recommended Actions for LHON Carriers


D Daily W Weekly M Monthly A Annual

Medical & Scientific Journals


Key scientific articles and journals with supporting evidence used in LHON research and treatment guidelines:

Clinical Studies


Additional Resources


Genetic Counseling

Professional genetic counseling services for LHON families

Find Counselor

Low Vision Support

Rehabilitation services and assistive technologies

Learn More

Patient Advocacy

LHON.org and UMDF patient support groups

Get Support